STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA

Their core work

STAB VIDA is a Portuguese biotech SME specializing in genomic services, next-generation sequencing (NGS), and molecular diagnostics. They provide biological sciences research services — from DNA sequencing and clinical diagnostics to participation in nanomedicine and cancer biomarker development. Their H2020 portfolio shows them operating at the intersection of diagnostics technology and nanoparticle-based therapeutic platforms, contributing sequencing and molecular biology expertise to international research consortia. They have coordinated projects developing NGS-based clinical diagnostic kits and blood tests for lung cancer detection.

What they specialise in

How they've shifted over time

STAB VIDA's early H2020 work (2014-2016) centered on diagnostic imaging and nanostructures for neurodegenerative disease, with keywords around Alzheimer's, MRI, PET, and theragnostics. From 2017 onward, their focus shifted decisively toward oncology and immunotherapy — lung cancer blood tests, immune-directing nanomaterials, tumor vaccination, and APC targeting. This trajectory shows a company moving from general molecular diagnostics and neuroimaging support toward cancer-focused precision medicine and immuno-nanomedicine.

STAB VIDA is converging on cancer precision medicine, combining their sequencing core business with nanomedicine-based immune modulation — expect continued focus on oncology diagnostics and nano-immunotherapy.

How they like to work

STAB VIDA splits evenly between leading and joining projects (2 as coordinator, 2 as participant), showing they can both drive a project and contribute specialized expertise to larger teams. With 39 unique partners across 22 countries from just 4 projects, they operate in broad, international consortia rather than small closed teams. This breadth suggests they are comfortable working across cultures and institutions, making them an adaptable partner for new consortium builders.

Despite only 4 projects, STAB VIDA has built a remarkably wide network of 39 partners across 22 countries, indicating involvement in large multi-national consortia. Their base in Portugal positions them as a Southern European hub with strong pan-European reach.

What sets them apart

STAB VIDA combines commercial genomic sequencing services with active participation in frontier nanomedicine research — an unusual profile for a biotech SME. Where many sequencing companies stay purely in service delivery, STAB VIDA co-develops diagnostic products (NGS kits, liquid biopsy blood tests) through EU-funded R&D. This dual identity — service lab plus innovation partner — means consortia get both research capacity and a pathway to market validation from a single partner.

Highlights from their portfolio

• LungCARD
  Their largest project (EUR 603K) as coordinator, developing a blood test for guiding lung cancer therapy — directly tied to their commercial diagnostics mission.
• DIRNANO
  Most recent project (2020-2024) at the frontier of immune-directing nanomaterials for tumor therapy, signaling their strategic move into immuno-oncology.